Trial Profile
Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Mar 2011
Price :
$35
*
At a glance
- Drugs Nateglinide (Primary) ; Glibenclamide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 24 Mar 2011 Secondary endpoint '2h-plasma-glucose-level' has not been met
- 24 Mar 2011 Primary endpoint 'Fasting-glucose-level' has not been met
- 24 Mar 2011 New trial record